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Abstract 
Introduction: Inhibition of self-reactive T cells through induction of antigen-specific immune 
tolerance holds the promise of effective treatment of autoimmune pathology with few side 
effects and preservation of normal immune functions. In multiple sclerosis (MS) several 
approaches have been tested already in clinical trials or are currently ongoing with the aim to 
inhibit myelin-reactive immune responses.  
Areas covered: We will give an overview of recent and ongoing strategies to inhibit specific 
immune responses in MS, including different applications of myelin peptide-based 
approaches, T cell vaccination, DNA vaccination and antigen-coupled cells.  
Expert opinion: Despite difficulties in translation of antigen-specific therapies in MS, novel 
approaches have the potential to effectively induce immune tolerance and ameliorate the 
disease. To improve efficacy of treatments, future trials should include patients in the early 
phases of the disease, when the autoimmune response is predominant and immune reactivity 
still focused. The target antigens are not fully defined yet, and robust immunomonitoring 
assays should developed to provide mechanistic proof-of-concept in parallel to showing 
efficacy with respect to inhibiting inflammatory disease activity in the central nervous system 
(CNS).  
 
  
1 Introduction: 
Targeted inhibition of antigen-specific T cells can be viewed as the most direct and specific 
means of correcting pathogenic immune responsiveness, which underlies many organ-specific 
autoimmune diseases [1-3]. The main goal of such approaches is to stop or reverse an 
autoreactive T cell response by specifically inducing immune tolerance to the target self-
antigens. Compared to unspecfic immunomodulatory or immunsuppressive interventions, 
antigen-specific therapies have the advantage that they should in principle only affects the 
pathogenic immune response without altering physiological immune responsiveness. 
Extensive pre-clinical research on basic mechanisms of autoimmunity and immune tolerance 
facilitated translation of several therapeutic approaches in patients with autoimmune disease 
in general and multiple sclerosis (MS) in particular. Although the etiology of MS is as yet not 
fully understood, all current therapeutic approaches are based on the concept that the disease 
is driven by an immune response directed against self-antigens in the central nervous system 
(CNS) [4]. Based on extensive research in the animal model of MS, experimental 
autoimmune encephalomyelitis (EAE), and the fact that the HLA-DR15 haplotype confers 
most of the genetic risk to develop MS, it has long been considered the prototype of a CD4+ 
T cell-mediated disease [4]. However, there is increasing evidence for a  role of several other 
compartments of the immune system including CD8+ T cells, B cells/antibodies, and 
cytokines/chemokines. Despite these data, there is little doubt that CD4+ T cells play a central 
role in orchestrating the pathogenic immune response in MS patients, and they are 
consequently viewed as important target for therapeutic intervention. Also, while the 
armamentarium of approved therapies for MS, which includes small molecule drugs, 
monoclonal antibodies and other biologics (peptidic compounds, interferon-beta) has grown 
substantially in the last two decades, and these therapies offer moderate to high efficacy, all 
inhibit the immune response in an unspecific manner,require long-termapplication and are 
associated with sometimes serious- to life-threatening risks.  Targeting the pathogenic 
autoreactive T cell response by direct intervention offers the opportunity to treat the disease 
with few side effects and has the potential for long-lasting clinical benefit, since it aims to 
correct the causes of autoimmune diseases at their roots. Approaches that aim at a specific 
inhibition of autoreactive T cells are subject of this review. 
 
1.1 Principles of antigen-specific / T cell mediated therapies 
Reactivity against self is inherent to the function of the adaptive arms of the immune system, 
i.e. antibodies and T cells, and under physiological conditions multiple safeguards avoid that 
high affinity and pathogenic autoantibodies or autoreactive T cells develop. Hence, 
pathogenic autoimmunity is avoided at several developmental steps, first in the thymus 
(central tolerance), where thymocytes are eliminated by clonal deletion if they recognize self-
HLA together with self-peptides with high avidity [5]. It is important to note that despite this 
first checkpoint, where high avidity self-reactive T cells are eliminated, those that are 
positively selected and constitute the peripheral T cell repertoire have all been selected on 
self-HLA/self-peptide complexes, which means that they all are in principle autoreactive. 
Therefore, further safeguard mechanisms are required to maintain immunologic tolerance at 
the level of peripheral immune activation. All therapeutic strategies aiming to induce antigen-
specific tolerance operate at the level of peripheral tolerance, since it is not possible to 
influence central tolerance mechanisms. Antigen-presentation and activation of autoreactive 
effector T cells are the main processes, which are targeted by tolerization approaches.  
The most essential process in the activation of an effector T cell is the formation of the 
immune synapse between the T cell and an APC (Figure). This highly specific interaction 
requires formation of the trimolecular complex (signal 1), engaging the HLA class II 
molecule of the APC, the antigenic peptide bound to the HLA class II molecule and the T cell 
receptor (TCR). Formation of a stable immune synapse is further dependent on the interaction 
of different molecules between the APC and the T cell, which can have both stimulatory or 
inhibitory effects (signal 2). Peripheral tolerance can act at different levels in the formation of 
the immune synapse (Figure). In the absence of costimulatory signals, i.e. signal 2, upon 
engagement of the trimolecular complex a T cells is rendered unresponsive to antigen 
stimulation, a state that is referred to as anergy [6]. Anergy can persist even if the antigen is 
later presented by a fully competent APC, however it is in principle transient and reversible 
and can be overcome by interleukin-2 [7,8]. Engagement of a negative second signal pathway 
between the APC and the T cell (eg CTLA4/CD80 or CD86, PD1/PD1L) leads to clonal 
deletion through apoptosis of T cells [9-11]. Overactivation of the TCR in a pre-activated T 
cell might lead to apoptosis of the T cell by activation induced cell death (AICD), via the 
interaction of FasLigand with Fas [12-14]. 
Besides the above direct means of functionally silencing or eliminating an autoreactive T cell, 
autoreactivity can also actively be suppressed by indirect mechanisms that involve  regulatory 
T cells (Tregs) [15-17], and the latter cells have also been employed for tolerization 
approaches [18]. Neither Tregs nor any of the other abovementioned mechanisms usually 
maintains peripheral tolerance alone. Instead it is more likely that these act in concert and 
probably need to be broken at several levels before overt autoimmune diseases develop. Also, 
while mechanisms like anergy, insufficient- or too strong activation are supposedly more 
important for an early reduction in pathogenic T cell responses, the induction of Treg has the 
potential to lead to a long-term and stable inhibition of pathogenic, autoreactive T cell 
responses [19]. Furthermore, alterations in the cytokine milieu with the aim to skew the 
effector subsets from a proinflammatory (ie. TH1, TH17) to an anti-inflammatory phenotype 
(TH2, Tr1), a process referred to as immune deviation, can lead to the induction and 
maintenance of immune tolerance [20]. 
 
2 Previous and current approaches of antigen-specific therapies in MS 
While the basic mechanisms of T cell tolerance involve the interaction with the trimolecular 
complex or induction of regulatory cell and/or cytokine responses the approaches used to 
achieve this inhibition of T cells differ in their methods as well as the route of administration 
(Figure). Many approaches focused on the specific self-peptide as the central structure of the 
trimolecular complex responsible for a stable interaction between the HLA and the TCR. 
When using synthetic peptides different routes of administration have been shown to induce 
tolerance. In MS, clinical trials were performed with mucosal, intravenous, sub-, intra- or 
epicutaneous application of peptides, which derived mostly from peptides of myelin basic 
protein (MBP) but also of other myelin proteins including myelin oligodendrocyte protein 
(MOG) and proteolipid protein (PLP) (Table). A different strategy relied on synthetic 
peptides, which had been modified in their interacting regions, i.e. altered peptide ligands 
(Table). As opposed to myelin peptides the TCR of a pathogenic myelin-specific T cell 
population can also be used as target structure, either through administration of peptides 
corresponding to regions of the complementarity determining region of TCRs or injection of 
attenuated pathogenic myelin-specific T cells (Table). Both approaches have been tested in 
clinical trials in MS patients. Finally intravenous infusion of autologous, antigen-coupled 
cells is a novel approach currently tested for treatment of MS. 
 
2.1 Myelin peptide-based approaches to induce tolerance in MS 
2.1.1 Mucosal administration of myelin peptides 
Induction of tolerance via oral or mucosal administration of peptides is an appealing approach 
not only because of advantages for patients with regard to applicability but also with regard to 
its favorable safety profile in preclinical studies [20]. The immunologic mechanisms of oral 
tolerance involve clonal anergy or deletion when given at a high dose whereas low dose 
treatment leads to bystander suppression through the release of suppressive cytokines, such as 
TGF-ß, IL-4 or IL-10 by regulatory T cells [21]. However, despite promising results in 
preclinical models, both clinical phase I/II trials as well as a large phase III placebo-controlled 
trial with oral bovine MBP in 515 MS patients failed [22]. Nevertheless, discussion is still 
ongoing as to whether dosage or formulation of myelin might have influenced efficacy of the 
treatment and whether an unusually strong placebo effect in the phase III trial has contributed 
to the negative outcome of the phase III trial.  
 
2.1.2 Intravenous administration of myelin peptides 
An alternative approach has been the intravenous administration of peptides at high doses, 
with the aim to induce activation-induced cell death (AICD) in antigen-specific T cells. In 
phase I/II clinical trials soluble MBP peptide (MBP82-96) was well tolerated and showed 
favorable effect on disease progression in HLA-DR2-positive patients [23,24]. Based on these 
results a multicenter, randomized, double-blind, placebo-controlled, phase III trial was 
performed in 612 SPMS patients stratified for HLA-DR2 and HLA-DR4. MBP peptide (500 
mg) was administered i.v. every 6 months [25]. The trial failed to reach both the primary 
outcome, i.e. time to confirmed disability progression, or other secondary outcomes. No 
safety issues occurred, and the peptide was well tolerated. Immunological analyses from these 
patients have not been reported. Altogether further development of the approach has been 
stopped. Possible reasons for the failure of the strategy include the target population and the 
trial design. From the clinical perspective, induction of immune tolerance in MS will always 
remain a preventive measure. Thus, inclusion of patients with longer disease duration, who 
are in a phase of the disease where the autoimmune pathology might be less important, might 
have biased the results, since measures of neurodegeneration might not be the right outcome 
parameter. Another reason for the failure might have been the use of a single peptide. 
Although, the primary target antigen in MS is not known for certain, it is likely that several 
target antigens from different myelin proteins exist and that these might differ between 
patients and even change over time in individual patients. Analysis of peptide specific 
immune responses might have helped in the interpretation of the data. 
Intravenous injection of a solubilized MHC-peptide complex was used in another approach to 
induce antigen-specific tolerance, however, although the administration of the solubilized 
MHC-MBP84-102 complex was safe, it did not show a significant treatment effect in patients 
with SP-MS [26]. The latter group of patients was probably not the right target population for 
the study, which underscores the importance of choosing a proper trial design for such early 
proof-of-concept trials. 
In a similar strategy, recombinant single chain, two domain MHC class II molecules 
covalently coupled to peptides were developed. For the treatment of MS a RTL (RTL1000) 
was developed, in which the immunodominant MOG35-55 peptide was covalently bound to 
the ß1-α1 domains of HLA-DR2. RTL1000 was tested in MS patients in a multicenter, 
double blind, phase I dose dose finding study study with the aim to determine the maximum 
tolerated does of a single iv. injection of RTL1000 [27]. Thirty-four MS patients were treated 
with increasing doses of RTL1000 or placebo and the study drug was well tolerated up to a 
dose of 60 mg. Overall there was no increase in disease activity. In EAE a similar dose, based 
on body surface area, was effective in prevention and treatment of DR2 transgenic mice with 
MOG35-55 induced EAE [28].  The company is currently preparing a phase II trial in MS and 
announced further development of this approach in other autoimmune disease like celiac 
disease, uveitis and rheumatoid arthritis. 
 
2.1.3 Subcutaneous/intradermal administration of myelin peptides 
Administration of a mix of 4 synthetic myelin peptides (ATX-MS-1467, Apitope Technology 
Ltd, licensed by MerckSerono) derived from MBP has been tested in 6 secondary progressive 
MS patients [29]. ATX-MS-1467 is currently being tested in a second phase I study in 40 
RRMS patients (ClinicalTrials.gov Identifier: NCT01097668) assessing the safety of the 
approach and comparing intradermal versus subcutaneous route of administration. The 
approach is based on the concept that the synthetic peptides induce a strong regulatory T cell 
response via IL-10- producing T cells. The approach offers the advantage of using a set of 4 
myelin peptides derived from MBP, however does not include peptides from other myelin 
proteins.  
 
2.1.4 Epicutaneous administration of myelin peptides 
Recently, transdermal administration of a mixture of three myelin peptides (MBP 85-99, 
MOG 35-55, PLP139-151) has been tested in a phase II placebo-controlled trial in thirty 
RRMS patients [30]. Patients were randomized to receive placebo or two doses of peptide 
mixture (1 mg of each peptide vs 10 mg of each peptide). The primary endpoint was the 
cumulative number of contrast enhancing lesions on MRI in the 1 mg treatment group 
compared to placebo. The trial met the primary endpoint in showing a reduction in MRI 
parameters of inflammatory disease activity in patients treated with 1 mg of each peptide 
compared to placebo. This was paralleled by a reduction in the annualized relapse rate in the 
treatment group. The 10 mg treatment group did not differ from the placebo group with regard 
to primary and secondary outcome parameters, but the authors claim that the low number of 
patients treated with the 10 mg dose precluded statistical analysis. Intriguingly, 
immunological effects have been reported, showing reduction in myelin-specific T cell 
responses in peptide-treated patients compared to placebo and induction of Tr1 cells [31]. 
Moreover, histological analyses from skin biopsies at the site of application and samples from 
draining local lymph nodes revealed activated dendritic Langerhans cells in the skin and a 
population of granular dendritic cells in local lymph nodes. In summary, this is a promising 
approach given the easy applicability of the peptide product. Beneficial clinical effects are 
underscored by mechanistic studies suggesting induction of immune tolerance. 
 
2.1.5 Altered peptide ligands 
Altered peptide ligands (APL) are analogues of immunogenic peptides that have been 
modified by introducing one or few substitutions in amino acid positions essential for contact 
with the TCR but retain the MHC binding motif moieties. APLs can block T cell responses 
acting as partial agonists, antagonists or, as it has been demonstrated in an animal model of 
MS, by inducing a new T cell population with a Th2 phenotype that cross recognizes the 
native auto-antigen and mediates bystander suppression [32,33]. Based on these evidences a 
MRI- controlled phase II trial in MS with an APL derived from the immunodominant MBP 
peptide 83-99 was started. However, the trial had to be halted because 3 of 8 patients 
receiving high dose APL developed relapses [34]. The exacerbations were characterized by 
inflammatory disease activity on MRI, which was unusual with respect to the number of new 
inflammatory lesions or the size of lesions when comparing them to those during the patients 
previous disease history. Extensive analysis of myelin-reactive T cells demonstrated that the 
observed relapses were paralleled by a strong increase in the frequency of MBP83-99 reactive 
T cells in the peripheral blood and CSF. Furthermore, most APL- or MBP 83-99-specific T 
cells that were isolated during relapse had a proinflammatory phenotype and cross-reacted 
with the respective other peptide, which strongly indicated that APL immunization had 
expanded proinflammatory MBP 83-99-specific T cells and led to the clinical relapses. This 
result provides the so far strongest proof of concept in MS, that clonally expanded MBP-
specific T cells are able to induce inflammatory lesions in the CNS [34]. A much larger, 
placebo-controlled, multicenter trial with the same APL that compared 3 different doses and 
placebo was suspended because of the data from the above trial and hypersensitivity reactions 
in 9% of the patients. Differently from the first trial no increases in relapses have been 
observed and a reduction in the mean number of contrast-enhancing lesions as well as a 
tendency towards induction of Th2 cells have been reported [35,36]. While the exact reasons 
for the failure of the first APL trial remain unclear, a) the probably too high dose of peptide 
(50 mg s.c. weekly), b) the injection via an in principle immunogenic route, i.e. 
subcutaneously, and c) the unusual HLA-class II composition of the small group of patients 
with very few expressing HLA-DR15, probably all contributed.  
 
2.2 DNA vaccination 
The principle of this tolerization strategy is a heterotopic expression of a specific target 
antigen with the aim to induce antigen-specific tolerance. A DNA vaccine of whole human 
MBP protein (BHT-3009, Bayhill Therapeutics) was chosen as target antigen [37,38]. In 
practice, a plasmid encoding the auto-antigen is injected intramuscularly, which leads to low-
level expression of the antigen in muscle cells. The intramuscular application of BHT-3009 
was well tolerated and provided favorable trends regarding MRI data in MS patients with 
active disease [39]. This effect was paralleled by a marked decrease in peripheral blood Th1 
CD4+ T cells reacting against peptides from the three myelin proteins MBP, MOG and PLP 
and reduced titers of specific auto-antibodies in CSF to MBP but also PLP [39]. In a phase II 
trial in 267 RR-MS patients were randomized to receive either placebo or two doses of BHT-
3009 [40]. Treatment with BHT-3009 reduced the rate of new enhancing lesions during weeks 
28 to 48, but did not meet this primary endpoint. A recent post-hoc analysis suggested a 
protective effect of the low-dose BHT3009 (0.5 mg) on the evolution of new lesions to 
persistent black holes, which are thought to represent irreversible brain damage [41]. As an 
advantage compared to other tolerization strategies DNA vaccine offers the opportunity to 
combine expression of the auto-antigen with expression of anti-inflammatory cytokines in a 
single plasmid, which might enhance the efficacy. The strategy has succsesfully been tested in 
Type I Diabetes mellitus patients with a DNA vaccine encoding pro-insulin [42]. 
 
2.3 T cell receptor vaccination 
This approach involves administration of either attenuated autologous antigen-specific T cells 
or peptides from the complementarity determining regions (CDR) 2 or 3 of myelin reactive T 
cells with the aim to induce an immune response directed against these pathogenic T cells.  
Several studies tested T cell vaccination for treatment of MS using autologous myelin 
peptide-specific, attenuated T cells derived from peripheral blood lymphocytes or CSF [43-
51]. Overall, the treatment was well tolerated in MS patients. A reduction in the frequency of 
myelin-reactive T cells has been reported as well as a reduction in disease activity in several 
patients. Based on these encouraging results a randomized, double blind trial of autologous 
attenuated myelin-specific T cells has been performed in 26 relapsing-progressive MS 
patients receiving repeated subcutaneous administration of 1x106 attenuated myelin-specific T 
cells and compared 7 patients treated with sham injections [52]. T cells were derived from 
peripheral blood lymphocytes, which were stimulated with 9 myelin peptides from three 
proteins (MBP, MOG and PLP). The study demonstrated feasibility and safety of the 
approach and indicated significant efficacy on clinical parameters of disability as well as 
inflammatory disease activity in the treated group as compared to the sham treated patients. 
However, there was no difference in MRI parameters of disease activity.   
A randomized, placebo controlled, phase 2b trial using peripheral blood-derived myelin-
specific T cells, in-vitro expanded with six myelin peptides from MBP, MOG and PLP 
(Tovaxin®/Tcelna™; Opexa Therapeutics Inc.) was conducted in 150 RRMS and CIS 
patients [49]. Over 12 months the study drug was safe and well tolerated. Overall, there was 
no difference in the clinical and MRI parameters of efficacy, although a subgroup analysis 
suggested a benefit for Tovaxin® in treatment-naïve patients with high disease activity at 
baseline. Based on an open label dose escalation study showing favorable effects of Tovaxin 
on clinical and immunological parameters according to a press release by the company, 
Tcelna™ (licensed by MerckSerono) has been granted Fast Track designation by the U.S. 
FDA for the secondary progressive MS indication [50].  
Therapeutic vaccination using peptides from the CDR of myelin-reactive T cells from MS 
patients is a different approach aiming at modulation of autoreactivity. Administration of 
TCR peptides via monthly intramuscular injection has been tested in a double-blind pilot trial 
in 23 MS patients [53]. Six of the patients were responders to the therapy showing 
progression-free disease over 1 year, reduced MBP-specific T cell responses and induction of 
IL-10. For further development of the approach, three peptides from TCR BV genes have 
been identified as best candidate targets out of approximately 1000 AV and BV genes from 
neuroantigen-specific T cells from 200 MS patients [54]. Intramuscular injection of the 
vaccine containing three CDR2 peptides (NeuroVax, Immune Response Biopharma Inc) has 
been tested in an open label study in 27 MS patients by monthly intramuscular injection over 
a period of 12 months. Following vaccination most patients remained stable with regard to 
disability, and a high frequency of IL10-secreting T cells could be measured in treated 
patients. This was paralleled by increased expression of FoxP3 in CD4+CD25+ regulatory T 
cells. The company recently announced a randomized, double-blind, multicenter, active 
controlled, parallel group study to assess the efficacy and safety of weekly intramuscular 
injection of NeuroVax compared to weekly Interferon-beta 1a i.m. in patients with MS.. 
 
2.4 Antigen-coupled cell tolerance 
A tolerization strategy, which looks very promising based on extensive experience in various 
animal models [8,19,55-67] uses autologous peripheral blood mononuclear cells (PBMC) 
pulsed with myelin peptides and chemically fixed with the cross linker 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC), as tolerogenic vaccine. In experimental 
autoimmune encephalomyelitis (EAE) this protocol not only prevented disease, but even 
effectively reduced the onset and severity of all subsequent relapses when given after disease 
induction, indicating that specific tolerance can downregulate an ongoing autoimmune 
response [68]. This regimen has also been shown to prevent epitope spreading and has proven 
excellent efficacy in animal models of different T cell-mediated autoimmune diseases, 
transplantation tolerance and allergy [19,69]. 
A first –in-man trial (ETIMS trial) was conducted in MS patients with the aim to assess the 
feasibility, safety and tolerability of this novel tolerization regimen, which employs a single 
infusion of autologous peripheral blood mononuclear cells chemically coupled with seven 
myelin peptides (MOG1-20, MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-
170 and PLP139-154). In the open-label, single center, dose escalation study, nine MS 
patients (7 relapsing-remitting and 2 secondary progressive; EDSS 1-5.5), who were off-
treatment for standard therapies were treated with a single infusion of ETIMS product. All 
patients had to show T cell reactivity against at least one of the myelin peptides used in the 
trial. Neurological, MRI, laboratory and immunological examinations were performed to 
assess the safety, tolerability and in vivo mechanisms of action of this regimen. Overall, 
administration of antigen-coupled cells was feasible, had a favorable safety profile and was 
well tolerated in MS patients. Compared to the pre-treatment observation period there was no 
increase in clinical and MRI parameters of disease activity by this regimen. Patients receiving 
the high dose (>1x109) of peptide-coupled cells showed a decrease in antigen-specific T cell 
responses following ETIMS therapy [70]. A multicenter phase IIa trial assessing efficacy and 
safety of ETIMS therapy in early RRMS patients is currently in preparation. Advantages of 
the approach are that tolerance can be simultaneously induced to multiple epitopes, thereby 
targeting both naïve and activated autoreactive T cells with multiple specificities. Further, in-
vivo the regimen has proven to block epitope spreading efficiently and relapses can be 
inhibited by tolerance to the spread epitope. From preclinical studies it is expected that a 
single intravenous infusion of peptide-coupled PBMC is able to induce long-term 
amelioration. Antigen coupled cell tolerance adds a completely new mechanism of tolerance 
to the field. There is evidence that at least two distinct mechanisms are involved, including 1) 
direct tolerance through failure of costimulation in T cells encountering antigen/MHC 
complexes on chemically-fixed antigen presenting cells (APC) [8], and 2) an indirect 
mechanism, through processing of antigens from EDC treated apoptotic cells by host APCs 
and re-presentation in a tolerogenic way [67,71] (Figure 1). 
 
2.5 Summary 
Several approaches aiming at antigen specific tolerance in MS have already been successfully 
tested in patients, with regard to safety of the treatment and immunological measures of 
immune tolerance. Only few approaches failed because of safety issues. However, with regard 
to clinical efficacy a major breakthrough has not been reached, yet. Further improvements in 
ongoing and future strategies can be made in the selection and range of target antigens, the 
immunological measures of immune reactivity and tolerance, but also in patient selection and 
trial design. Besides the above mentioned therapeutic strategies, which reflect the most 
important developments in the field, several novel and promising strategies are already in pre-
clinical development including the use of tolerogenic dendritic cells [72].  
 
3 Expert Opinion 
Despite many successes in animal models of MS and also other autoimmune diseases the 
translation of antigen-specific therapies to MS patients or in general to organ-specific 
autoimmune diseases resulted in several difficulties including lack of efficacy, or even disease 
exacerbation and hypersensitivity reactions. In our opinion, the pitfalls do, however, not only 
lie in clinical outcomes of safety and efficacy but also various immunological and conceptual 
aspects.  
 
3.1 Target antigens 
Over the last decades many groups have studied the immune response in MS patients [4]. 
Given the histopathologic evidence of a primary immune-mediated destruction of myelin with 
relative sparing of axons in lesions of MS patients antigens within the myelin sheath were 
thought to be the main targets of the immune response [73]. Thus, many researchers have 
focused on myelin-specific T cell responses in MS patients. Extensive research in animal 
models of MS supports the concept that the pathogenic immune response is primarily directed 
against myelin antigens. Consequently, research devoted most attention to the main myelin 
proteins MBP PLP, MOG, but also included CNPase, MOBP, OSP, and to a minor extent 
non-myelin proteins such as αB-crystallin and neuronal antigens [4]. Despite these efforts, a 
single target antigen could not be identified yet in MS, and several reasons may account for 
this fact. First, it is likely that the target antigen/s differ/s between patients depending on their 
HLA-class II background and other factors, and there is at least some evidence also in humans 
that it changes over time due to epitope spreading [74-76]. In EAE epitope spreading has been 
analyzed in detail and it could be shown that chronic demyelination leads to the generation of 
new T cell responses against multiple endogenous antigens and that these newly generated T 
cells are able to induce relapses [77,78]. Moreover, induction of tolerance against the spread 
epitope results in inhibition of further relapses [77]. Even though the evidence for epitope 
spreading is less solid in MS than in the EAE model, it has been demonstrated that the 
repertoire of activated T cells changes during the course of the disease [74-76]. Therefore 
tolerization against myelin antigens in MS should be pursued early in the disease course and 
should target both naïve and activated autoreactive cells specific for multiple different 
antigens. 
Second, several different assays have been used to analyze myelin-specific T cell responses in 
MS, the most common analyzing either proliferation response or cytokine secretion. These 
assays vary considerably in the concentrations of antigens used or the number of T cells 
applied in the assay. Both these factors have to be considered in the interpretation of the data. 
Very high concentration of antigen can facilitate an immune response mediated by low 
avidity autoreactive T cells, which potentially reflect T cells with some degree of cross-
reactivity against myelin antigens, but higher avidity for different antigens. These cross-
reactive T cells are unlikely to be related to the primary autoimmune processes in MS [79]. 
Lower concentrations of antigen might be more appropriate to identify myelin-reactive T cells 
with a high avidity for the target antigens, which are more likely to reflect a pathogenic 
immune response [79]. Myelin reactivity can be found in many healthy controls and the 
difference between MS and healthy controls might lie in the avidity and phenotypic 
characteristics of T cells. Further, the precursor frequencies of myelin-reactive T cells vary 
considerably across different studies and depending on which readouts have been used. The 
latter issue, i.e. the development and application of standardized and well-validated tests to 
measure the frequency and phenotype of autoantigen-specific T cells reliably over time in a 
single patient and groups of patients is a major and as yet not fully resolved problem. Many 
factors need to be considered in this context, and further development is clearly needed to 
improve suitable ex vivo readouts to prove the biological effect of tolerization approaches.  
For future trials it will be essential to provide validated and robust assays to assess antigen-
specific T cell responses, their frequencies and functional phenotypes.  
Although CD4+ T cells are considered to be crucial in orchestrating the pathogenic immune 
response in MS, it is likely that several other compartments of the immune system add to the 
autoreactive inflammation. The discovery of anti aquaporin4 antibodies (AQP4-Ab) in 
neuromyelitis optica demonstrated the importance of humoral and B cell mediated immune 
responses in a demyelinating disease [80]. An important role of B cell-mediated effector 
functions in MS has also been supported by clinical trials demonstrating efficacy of B cell 
directed therapies in RRMS patients [81]. Recently, antibodies against Kir4.1, a potassium 
channel, have been described in MS patients [82]. Thus, future tolerization strategies in MS 
should assess their efficacy in reducing both T and B cell mediated immune responses, as well 
as other immune compartments. Consequently, the search for biomarkers able to reflect 
induction of immune tolerance throughout different immune compartments through a specific 
tolerance signature will be essential not only for a better understanding of the treatment 
effects but also the pathogenesis of the disease. 
In summary, although a single target antigen could not be identified in MS the evidence for 
myelin proteins as importat targets of the autoimmune response is fairly robust across 
different studies in several cohorts of MS patients. Given the possibility that the target 
antigens differ between patients and may even change throughout the disease, because of 
epitope spreading, tolerization strategies, which offer the possibility t target various antigens 
at the same time are more likely to be successful in MS. 
 
3.2 Patient population and trial design 
Many trials, which tested new antigen-specific therapies in MS, included progressive patients 
with long-standing disease course, However, at later stages of the disease, antigen-specific 
autoimmune inflammation might be less relevant than during the earlier stages of the disease, 
and patients in the progressive phase of the disease are usually not amenable to any of the 
currently available treatments. Hence, trying to provide proof-of-concept and show efficacy in 
the progressive stage is difficult if not impossible, and several of the above approaches were 
unfortunately mainly tested in progressive patients. Further, as already mentioned above it is 
likely that the specific immune response spreads to several antigens during the disease. 
Consequently, in future therapeutic trials aiming at antigen-specific tolerance it will be crucial 
to start treatment early in RR-MS patients, ideally within the first five years from onset of the 
disease. Patients should be tested for their reactivity before inclusion in the trial, and this 
should be a pre-requisite for treatment to follow its immunological effects. Clinical trials 
should be accompanied by appropriate mechanistic studies to measure the effect of the 
treatment on the immune system, not only as a relevant safety parameter but also as a measure 
of biological effect, i.e. if antigen-specific tolerance has indeed been induced. The proof-of-
concept that induction of tolerance against specific antigens is able to halt the disease will 
only be possible by efficient combination of immunologic and clinical/MRI based outcome 
parameters. For several tolerization strategies we further expect that they will at least in part 
depend on the specific HLA-class II background of individuals. Thus, the HLA-class II type 
of enrolled patients has to be analyzed and taken into consideration in the interpretation of the 
data. 
Early phase trials in RRMS aiming to assess safety and preliminary efficacy should include 
MRI as relevant outcome parameter. Since clinical efficacy can only be judged by large-scale 
phase IIb and III trials, which require large patient numbers and long study periods, MRI 
measures are considered the best validated biomarkers and are the recommended outcome 
measure for mechanism of action-oriented phase II clinical trials [83,84]. MRI parameters are 
ideal for correlating inflammatory activity in the CNS with immunological parameters 
reflecting the mechanism of action of the therapy. Obtaining serial and longitudinal MRI data 
also serves as a sensitive safety measure [34].  
 
4 Conclusion 
In summary, induction of immune tolerance in pathogenic T cells remains the only 
therapeutic strategy with the potential to treat autoimmune disease at its roots and thus being 
able to cure the disease. Despite the fact that several attempts in MS patients failed due to 
either side effects or lack of efficacy, novel strategies hold the promise that the goal of 
immune tolerance can still be reached. Several key point have to be considered in future 
clinical development of such approaches. First, strategies should aim to induce tolerance to 
several myelin epitopes simultaneously. Second, future clinical trials should focus on patients 
early in the disease, when autoreactive inflammation is predominant and epitope spreading 
still limited. Third, robust immunological assays should be developed to follow antigen-
specific T cells in treated patients, measure immunological outcome parameters, and provide 
information on the mechanism of action of therapy and immune tolerance.   
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Figure: Antigen specific approaches to induce immune tolerance in MS 
The figure depicts the central structures targeted by current approaches to induce antigen-
specific tolerance in MS.  
Panel A: shows the trimolecular complex, consisting of the MHC, the specific peptide and the 
TCR. Interaction in these structures can lead to anergy, apoptosis of T cells or anti-
inflammatory cytokine secretion (bystander suppression). Induction of regulatory T cells is an 
additional mechanism for induction of tolerance.  
Panel B: Induction of tolerance by antigen-coupled cells leads to apoptosis of coupled cells, 
which are phagocytosed by dendritic cells or macrophages and re-present the antigens in a 
tolerogenic way. 
 
Table: Overview on recent and ongoing strategies to induce tolerance in MS.  


Table: Overview on recent and ongoing strategies to induce tolerance in MS. 
 
Antigen specific 
therapy 
Treatment     RoA1 Tolerogen MS 
course 
n Trial design Result / Ref Immune response 
Transdermal myelin 
peptides 
Synthetic myelin 
peptides 
t.d. peptide RR 30 RCT Safe, Reduced relapse 
and MRI lesions / 30, 31 
Induction of Tr1 cells 
Apitope Synthetic peptides sc. / id. peptide SP 6 Open label not published / 29 Induction of IL10 Tr1 cells 
DNA vaccine  
(BHT-3009) 
Plasmid encoding 
full length human 
MBP 
i.m. DNA RR, SP 267 Double blind, RCT Safe, well tolerated, 
favourable on MRI / 40 
Downregulation of antigen 
specific cellular and 
humoral immune response 
MBP8298 Soluble peptide 
(MBP82-98) 
i.v. peptide SP 612 Double blind, RCT Benefit in HLA 
DR2/DR4 patients / 25 
  
Soluble MHC loaded 
with peptide 
Solubilized complex 
of DR2 with MBP 
 peptide/MHC 
complex 
SP 33 Double masked, 
dose escalation 
Safe, no effect on clinical 
activity / 26 
No tolerization effect 
APL - CGP77116 Altered peptide 
ligand 
s.c. peptide RR 8 Open label, MRI 
controlled 
Stopped due to 
exacerbations / 34 
Activation of MBP specific 
T cells / induction Th2 
response 
  Altered peptide 
ligand 
s.c. peptide RR 142 Double blind, RCT Stopped due to 
hypersensitivity / 35 
Induction Th2 response 
TCR vaccination Trivalent TCR 
peptide vaccine 
 peptide RR, SP 27 Open label no progression in 
disability / 55 
Induction of TCR specific 
responses, Induction of 
IL10 and FoxP3 T cells 
T cell vaccination Autologous myelin 
reactive T cells 
i.v. cell RR, CIS 150 RCT Safe, well tolerated, no 
benefit on clinical and 
MRI parameters / 50 
  
  Autologous myelin 
reactive T cells 
i.v. cell RP 26 Double-blind, RCT 
(sham-controlled) 
reduction in clinical 
disease activity, no effect 
on MRI / 52 
reduction in myelin reactive 
T cells 
  Autologous myelin 
reactive T cells 
i.v. cell RR, SP 5 open label Safe, well tolerated / 47  
T cell receptor 
ligands 
Recombinant HLA-
DR2/MOG35-55 
construct 
i.v. peptide-HLA 
construct 
RR 34 double blind, phase 
I dose escalationl 
safe well tolerated, target 
dose 60 mg / 27 
  
Antigen coupled 
cells 
Autologous PBMC 
chemically coupled 
with 7 myelin 
peptides 
i.v. cell RR, SP 9 Open label, MRI 
controlled 
Safe, well tolerated / 71 Downregulation of antigen 
specific cellular immune 
response 
 
1 RoA: Rout of administration; t.d.: transdermal; s.c.: subcutaneous; i.d.: intradermal; i.v.: intravenous; RR: relapsing-remitting; SP secondary progressive; RCT_ 
randomized controlled trial 
 
 
